Global (China, EU,Japan,India) Immunotherapeutics Market 2016: Volume, Share,Growth, Analysis and Forecast to 2021

Immunotherapeutics Global Market

Immunotherapy is the treatment given to suppress or amplify the immune response of a person using immunomodulators. The amplification of immune response is called as activation immunotherapy and the suppression of the immune response is called suppression immunotherapy. The global immunotherapeutics market is divided based on the segments, application and geography. Based on the segments, the immunotherapeutics are divided into monoclonal antibodies, vaccines, checkpoint inhibitors and non specific therapies. By application, the immunotherapeutics are divided into oncology, inflammatory disease, CNS and others. There are many cancer types such as lung cancer, melanoma, head and neck cancer, leukemia, colorectal cancer (CRC), lymphoma and others.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/211755-immunotherapeutics-global-market-forecast-to-2021

Geographical wise North America is the largest market, followed by Europe and Asia-pacific. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the immunotherapeutics market. Growth in the Asian market is attributed to rising incidence of target diseases, growing geriatric population and better healthcare initiatives by governments and various private organizations.
The immunotherapeutics global market is expected to grow at CAGR of 4.7% to reach $138.9 billion by 2021. The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs. In addition to this, emerging Asia Pacific and Latin American countries engaging in immunotherapeutics development and increasing government funding are some of the opportunities that are propelling the growth of the market.  However, the high cost of the drug development process with a threat of failure in the end stage and reimbursement issues are hampering the growth of the market. The threat to the immunotherapeutics market is reimbursement issue.

Access Complete Report @ https://www.wiseguyreports.com/reports/211755-immunotherapeutics-global-market-forecast-to-2021

The global immunotherapeutics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the immunotherapeutics market are AbbVie (U.S.), Amgen (U.S.), Biogen (U.S.), Bristol-Myers Squibb (U.S.), Celgene (U.S.), Johnson & Johnson (U.S.), Merck &Co., Inc (U.S.), Novartis (Switzerland), Pfizer (U.S.) and Roche (Switzerland).

Leave An Enquiry @ https://www.wiseguyreports.com/enquiry/211755-immunotherapeutics-global-market-forecast-to-2021

Table Of Contents

1 EXECUTIVE SUMMARY 16

2 INTRODUCTION 22

2.1 KEY TAKE AWAYS 22

2.2 REPORT DESCRIPTION 22

2.3 MARKETS COVERED 24

2.4 STAKEHOLDERS 25

2.5 RESEARCH METHODOLOGY 26

2.5.1 MARKET SIZE ESTIMATION 27

2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 30

2.5.3 SECONDARY SOURCES 31

2.5.4 PRIMARY SOURCES 32

2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 32

2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 34

2.5.7 ASSUMPTIONS 34

3 MARKET ANALYSIS 36

3.1 INTRODUCTION 36

3.2 MARKET SEGMENTATION 37

3.3 FACTORS INFLUENCING MARKET 38

3.3.1 DRIVERS AND OPPORTUNITIES 39

3.3.1.1 Increasing incidence of immunological diseases such as cancer, autoimmune and infectious diseases 39

3.3.1.2 High potency of (antibodies) over small molecule drugs 39

3.3.1.3 Mutual agreements among companies from drug development to commercialization 40

3.3.1.4 Increasing importance of cart therapies 40

3.3.1.5 Adoption of biological therapies in disease management 41

3.3.1.6 Emerging asia pacific and latin american countries engaged in the development, commercialization and distribution of immunotherapy

drugs 42

3.3.1.7 Increasing government funding 42

3.3.2 RESTRAINTS AND THREATS 43

3.3.2.1 High cost of drug development process with a threat of failure in end stage 43

3.3.2.2 Reimbursement issues 44

Continued…..

For more information or any query mail at [email protected]

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Posted by Vivian Dsena on Thursday December 22 2016, 5:04 AM EDT. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0